mix from ROW markets and API sales. The new ANDA launches, favourable forex and steady growth in India formulations kept EBITDA flat despite price erosion of its US portfolio by 8%. The forex loss of Rs1.3bn have impacted PAT to 72% QoQ decline in Q3FY19. Overall GNP's revenues were marginally better than expected considering the benefits of key launches (gWelchol, gVagifem, Tacrolimus, gNitrostat, gMupirocin) in US and better traction in India. The management guided for...